UK: 7%, 4%/6%, 16%/79%/2%/4%. Within each country, burden of type 2 diabetes tended to increase with age among diabetic individuals (all-age, 18-24, 25-34, 35-44, 45-54, 55-64, 65-69 yrs: % pts):
PDB9 ESTIMATED INCIDENCE OF TESTOSTERONE DEFICIENCY IN AGING BRAZILIAN MEN AND THE CONSEQUENT COSTS OF NEW CASES OF OSTEOPOROSIS-RELATED HIP FRACTURES
Bahia L 1 , Teich V 2 1 Brazilian Society of Diabetes, Rio de Janeiro, Brazil, 2 MedInsight, Rio de Janeiro, Brazil OBJECTIVES: This study aimed to model the increase in osteoporosis-related fractures and the associated costs related with aging and testosterone deficiency (TD) in the male population above 65 years in the Brazilian Private Health System (PHS). METHODS: Population-based prospective cohorts established age-specific annual incidence rates of testosterone deficiency and the prevalence of osteoporosis in men. Based on these estimates, projections for the number of cases of men with testosterone deficiency, osteoporosis and fractures in the Brazilian male population above 65 years were computed. The national costs associated with hip fractures have been previously recorded as R$ 24,051 (US$14,402) per event. RESULTS: Among 1,164,379 male individuals above 65 years under the Brazilian PHS, 27,130 new cases of TD would be expected in one year. Considering an osteoporosis incidence of 6% and 12.3% for men with normal and deficient testosterone, respectively, 1709 new cases of osteoporosis attributed to TD would be expected. This would result in an annual absolute increase of 0.16% in non-vertebral fracture incidence in men between 65-69 years; 0.24% between 70-74 years; 0.32% between 75-79 years and 0.40% above 80 years. Each of these absolute increases represents a 105% relative increase in the incidence of non-vertebral fractures between men with TD relative to men without TD. Seventy-one new non-vertebral fractures and 13 new cases of hip fractures would be expected, resulting in incremental costs of R$318,002 (US$190, 420) for the Brazilian PHS. CONCLUSIONS: Male aging is associated with gradual decrease in circulating testosterone, which may be detrimental to bone. This model suggests that, for the Brazilian male population above 65 years, testosterone deficiency is associated with a significant increase in new cases of osteoporosis-related fractures in one year. Diagnosis and proper treatment of this condition could have a favorable impact in the prevention of this costly complication. For the present analysis patients with missing values for LDL-c, HDL-c or triglycerides (TGs) were excluded. Individual patient lipid profiles were compared with the recommended lipid targets for diabetic patients by the latest ADA consensus. RESULTS: A total of 493 patients were recruited, and 338 included in this analysis. Average age was 63.1 (SD 10.6) years, 46.7% were female, and mean time from diabetes diagnosis was 8.6 (SD 5.3). The lipid parameter most frequently not at target was LDL-c (79.6%), followed by TGs (42.9%) and HDL-c (37.6%). 17.5% of patients had the three lipid parameters out of goal, and 31.4% had two of them not at target. Out of the 338 patients only 20 (a 6% approx.) presented all three lipid parameters at the recommended level. CONCLUSIONS: diabetic patients that start oral combination therapy with either MF+SU or MF + a PPARg agonist, very frequently have their lipid parameters not at recommended level. A greater focus is required to comprehensively manage their lipid profile, and reduce the cardiovascular risk associated with it.
PDB11 POTENTIAL IMPACT OF LIPID CONTROL AND SUBSEQUENT CARDIOVASCULAR (CV) RISK REDUCTION IN T2DM POPULATION TREATED WITH ORAL COMBINATION THERAPY (OCT) RECAP-DM STUDY
Nocea G 1 , Melero M 2 , Caloto MT 2 ,Yin D 3 1 MSD Spain, Madrid, Spain, 2 Merck, Sharp & Dohme, Madrid, Spain, 3 Merck & Co., Inc, Whitehouse Station, NJ, USA OBJECTIVES: Diabetic patients are at CHD greater risk than the general population. Therefore these patients will benefit from optimal care based on CHD risk evaluation. We assessed the potential impact of risk factors (RF) management on the cardiovascular (CV) risk among T2DM population. METHODS: A retrospective cohort study was conducted in Spain (2006) (2007) . Patients were aged Ն30 years at time of T2DM diagnosis and had added sulphonylurea or PPARg agonist to previous metformin. Patient RFs were assessed for attainment of guideline-defined optimal values. The data for these patients correspond to their last available measurements before add-on therapy. Five-year CV risk was estimated with a diabetic-specific model. An array of scenarios were created simulating patient adequately controlled LDL-C, both LDL-C and HDL-C, all three lipid parameters and all modifiable RFs (the previous plus smoking, SBP and HbA1c) . RESULTS: A total of 318 patients were included in this analysis. Average age 63.1 (SD 10.6) years and 47% were female. Less than 20% of the patients presented LDL-C at target levels and~60% of patients show HDL-C and/or triglycerides at the recommended levels. Among these patients SBP and HbA1c were~20% at target levels. Actual 5-years risk estimate was 51.6% (SD 0.3). The proportion of maximum potential CV Risk Reduction (calculated as Absolute Risk Reduction [ARR] divided by maximum ARR [ARR/MaxARR]), by simulated scenarios were: 42.4% (if LDL-C at target), 58% (if LDL-C and HDL-C at target); 67.5% (if all three lipid-parameters at target); and if all modifiable RF were at target for all patients the estimated risk was 31.1% and the maximum risk reduction 100%. CON-CLUSIONS: T2DM patients starting OCT frequently have their lipids not at target increasing their CV risk. Hence to reduce this risk it is required to comprehensively manage them in order to achieve the maximum benefit.
PDB12 ASSOCIATION BETWEEN HYPOGLYCEMIA EPISODES AND CHANGES IN THE SULPHONYLUREA TREATMENT PATTERN IN TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS. RECAP-DM SPANISH COHORT STUDY
Caloto MT 1 , Nocea G 2 ,Yin D 3 1 Merck, Sharp & Dohme, Madrid, Spain, 2 MSD Spain, Madrid, Spain, 3 Merck & Co., Inc, Whitehouse Station, NJ, USA OBJECTIVES: To assess the association of patient self-reported hypoglycemic-symptoms with dose reduction of sulphonylurea or change to another glucose-lowering drug class in adult patients with T2DM on oral anti-hyperglycemic therapy in Spain. METHODS: A retrospective study included patients Ն30 years at time of T2DM diagnosis that had added SU or PPARg-agonist to previous MF. The information was extracted from the patients' clinical charts, for up to 7 months baseline period (before SU or PPAR addition) and for a minimum of one year follow-up period (between therapy addition and date of survey), including: patients' demographic characteristics, glucose lowering therapy and HbA1c. Patient-reported hypoglycemic episodes during the year prior to study enrollment were collected, and patients were grouped according to the most severe episode they had reported. Patients that had not received a SU anytime in that period, and those that received insulin anytime during this period were excluded from the analysis. RESULTS: A total of 493 patients were recruited, and 323 included in this analysis. Average age was 64 years and 46.5% were female. Average time for the initiation of oral combination therapy was 2.9 years. Their average HbA1c at baseline was 8% and 7.1% at the end of follow-up period.
During the year prior to study enrollment, 119 patients (37%) reported hypoglycemic episodes; 75% only mild symptoms (no interruption of daily activities) and 25% at least one moderate (some interruption of activities) or severe/very severe symptoms (requiring non-medical/ medical assistance). A total of 12.4% of the patients had their SU dose reduced, suspended or replaced for either a glinide or a PPAR: 9% of patients without hypoglycemic symptoms, 15.6% of patient with mild symptoms and 24.1% of patients with from moderate to very severe hypoglycaemic symptoms (Chi-squared, p = 0.04). CONCLU-SIONS: Patient-reported experience of hypoglycemic symptoms was associated with higher odds of changing the SU treatment pattern.
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PDB13
REMUBURSEMENT OF LONG-ACTING INSULIN ANALOGS IN POLAND: A BUDGT IMPACT ANALYSIS
Rys P 1 , Gasiorowski M 1 , Lis J 2 , Gierczynski J 2 , Plisko R 1 1 HTA Consulting, Krakow, Poland, 2 Sanofi-Aventis sp. z o.o, Warszawa, Poland OBJECTIVES: The aim of the analysis was to estimate the budget impact of including long-acting insulin analogs (LAA) in the reimbursement list. METHODS: The reimbursement list in Poland currently includes several human insulin products, but LAA are not reimbursed, therefore only few patients receive them. This analysis was performed from the public payer perspective (National Health Fund). A 5-year time horizon was adopted. Prognosis was based on the assumption that basal insulin sales will increase in the same way as in the past 12 years in Poland. Percent of market share in basal insulin market were estimated based on other European countries. Four different reimbursement scenarios were considered: Scenario 1 (100% reimbursement of LAA for all insulin-treated patients) and scenario 2 (50% reimbursement for all insulin-treated patients), scenario 3 (100% reimbursement for special patient population) and scenario 4 (50% reimbursement for special patient population). Special patient population was defined as patients who did not obtain the desired metabolic effect with their currently used insulin regimen and/or experienced recurrent hypoglycaemia, particularly nocturnal. RESULTS: In case of 100 % reimbursement of LAA (scenario 1), the expenditures for basal insulin will increase by 19,598 mln PLN in 2007 and by 52,403 mln PLN in 2011. In scenario 2, the expenditure will increase by 3663 mln PLN and 8,01 mln PLN in 2007 and 2011 respectively. In scenario 3, the expenditure will increase by 11,072 mln PLN and 41,812 mln PLN in 2007 and 2011 respectively. In scenario 4 the expenditure will increase by 2970 mln PLN and 6589 mln PLN in 2007 and 2011 respectively. CONCLUSIONS: This analysis shows that 100 % reimbursement of LAA for all insulin-treated patients (scenario 1) will be associated with the highest increase in drug expenditure In Scenarios 2-4, expenditure will rise to a smaller extend due to restriction to special patient population and/or co-payment.
PDB14 LARGE IMPACT OF ANTIDIABETIC DRUG TREATMENT AND HOSPITALIZATIONS ON ECONOMIC BURDEN OF DIABETES MELLITUS IN THE NETHERLANDS DURING 2000 TO 2004
Van der Linden MW 1 , Plat A 1 , Erkens JA 1 , Emneus M 2 , Herings RMC 1 1 PHARMO Institute, Utrecht, The Netherlands, 2 Novo Nordisk A/S, Bagsvaerd, Denmark OBJECTIVES: To estimate the burden of diabetes mellitus (DM) and its complications in The Netherlands. METHODS: The PHARMO Record Linkage System comprised among others linked drug dispensing, hospital and clinical laboratory data from approximately 2.5 million individuals in The Netherlands. Patients with DM were included in the study cohort during 2000-2004 if they used antidiabetic drugs or had HbA1c Ն6.5 mmol/l or had a hospitalisation for DM or a diabetic complication in the measurement year or in the preceding year. Controls free of diabetes were 1:1 matched to patients with diabetes, on birth year, zip code and gender. Complications (hospitalisations and dispensings for cardiovascular disease/eye problems/amputations) were classified into stages. Complications attributed to DM were estimated as complication stages 1 and 2 among patients minus those among controls. Drug costs
